|
WO2020198434A1
|
|
Use of il-2 for diagnosis of celiac disease
|
|
WO2019113037A1
|
|
Measurement of ccl20 after gluten exposure
|
|
CA3080716A1
|
|
Dosing regimens for celiac disease
|
|
EP3474881A1
|
|
Escalating dosage schedules for treating celiac disease
|
|
WO2018005688A1
|
|
Compositions and methods for diagnosing celiac disease using circulating cytokines/chemokines
|
|
US10473647B1
|
|
Peptides for use in treatment and diagnosis of type 1 diabetes
|
|
US2017218453A1
|
|
Use of HLA genetic status to assess or select treatment of celiac disease
|
|
US2017059582A1
|
|
Methods for diagnosing celiac disease using circulating cytokines/chemokines
|
|
US2017097346A1
|
|
Use of interleukin-2 for diagnosis of celiac disease
|
|
AU2015249378A1
|
|
Methods for diagnosing Celiac disease using circulating cytokines/chemokines
|
|
AU2014318889A1
|
|
Dosage of a gluten peptide composition
|
|
EP2970893A1
|
|
Placebo-controlled gluten challenge method
|
|
US2016238590A1
|
|
Compositions and methods related to oat sensitivity
|
|
AU2013204429A1
|
|
Compositions and methods for treatment of celiac disease
|
|
EP3269379A1
|
|
Compositions and methods for treatment of celiac disease
|
